ATE28864T1 - Amide-derivate. - Google Patents

Amide-derivate.

Info

Publication number
ATE28864T1
ATE28864T1 AT83303998T AT83303998T ATE28864T1 AT E28864 T1 ATE28864 T1 AT E28864T1 AT 83303998 T AT83303998 T AT 83303998T AT 83303998 T AT83303998 T AT 83303998T AT E28864 T1 ATE28864 T1 AT E28864T1
Authority
AT
Austria
Prior art keywords
different
same
alkyl
hydrogen
acylanilides
Prior art date
Application number
AT83303998T
Other languages
English (en)
Inventor
Howard Tucker
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10531878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE28864(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici Plc filed Critical Ici Plc
Application granted granted Critical
Publication of ATE28864T1 publication Critical patent/ATE28864T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
AT83303998T 1982-07-23 1983-07-08 Amide-derivate. ATE28864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8221421 1982-07-23
EP83303998A EP0100172B1 (de) 1982-07-23 1983-07-08 Amide-Derivate

Publications (1)

Publication Number Publication Date
ATE28864T1 true ATE28864T1 (de) 1987-08-15

Family

ID=10531878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83303998T ATE28864T1 (de) 1982-07-23 1983-07-08 Amide-derivate.

Country Status (23)

Country Link
US (1) US4636505A (de)
EP (1) EP0100172B1 (de)
JP (2) JPS5933250A (de)
AT (1) ATE28864T1 (de)
AU (1) AU556328B2 (de)
CA (1) CA1249823A (de)
CS (1) CS399991A3 (de)
DE (1) DE3372965D1 (de)
DK (1) DK322783D0 (de)
ES (4) ES8601106A1 (de)
FI (1) FI83770C (de)
GR (1) GR79232B (de)
HK (1) HK92690A (de)
HU (1) HU191296B (de)
IE (1) IE55941B1 (de)
IL (1) IL69217A (de)
LU (1) LU88769I2 (de)
MX (1) MX9203451A (de)
NL (1) NL950029I2 (de)
NO (2) NO164974C (de)
NZ (1) NZ204995A (de)
PT (1) PT77087B (de)
ZA (1) ZA835182B (de)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54115075A (en) * 1978-02-28 1979-09-07 Cho Lsi Gijutsu Kenkyu Kumiai Plasma etching method
FR2540495B1 (fr) * 1983-02-07 1986-02-14 Roussel Uclaf Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4921941A (en) * 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
US4970303A (en) * 1988-02-03 1990-11-13 Xoma Corporation Linking agents and methods
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
GB9305295D0 (en) * 1993-03-15 1993-05-05 Zeneca Ltd Therapeutic compounds
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
DE4420777A1 (de) 1994-06-15 1995-12-21 Bayer Ag Verfahren zur Herstellung von 4-Fluorthiophenol
WO1996000090A1 (en) * 1994-06-27 1996-01-04 Ionix Corporation Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
AU7604798A (en) * 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
DE19746512A1 (de) 1997-10-22 1999-04-29 Bayer Ag Verfahren zur Herstellung von Arylmercaptanen durch Hydrierung von Diaryldisulfiden
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
CA2341711A1 (en) * 1998-08-28 2000-03-09 Smithkline Beecham Corporation Process for making 2-amino-5-cyanophenol
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
HU223950B1 (hu) 1999-06-10 2005-03-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
ES2273725T3 (es) 1999-09-04 2007-05-16 Astrazeneca Ab Derivados de hidroxiacetamidobencenosulfonamida.
MY127036A (en) 1999-09-04 2006-11-30 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
IL149056A0 (en) * 1999-10-19 2002-11-10 Nobex Corp Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
NZ518552A (en) * 1999-10-27 2003-10-31 Nobex Corp Resolution of intermediates in the synthesis of substantially pure bicalutamide
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6828458B2 (en) 2000-05-25 2004-12-07 Biophysica, Inc. Topical antiandrogen for hair loss and other hyperandrogenic conditions
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) * 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
CA2420279C (en) * 2000-08-24 2011-07-19 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
PL361705A1 (en) * 2000-09-21 2004-10-04 Bristol-Myers Squibb Company Process for the preparation of n-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
HUP0302847A3 (en) * 2001-02-27 2005-05-30 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
RU2318517C2 (ru) 2001-05-16 2008-03-10 Новартис Аг Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
US7102026B2 (en) * 2001-06-13 2006-09-05 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing and isolating rac-bicalutamide and its intermediates
AU2002312431A1 (en) * 2001-06-13 2002-12-23 Biogal Gyogyszergyar Rt. Novel process for preparing rac-bicalutamide and its intermediates
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
US20060004042A1 (en) * 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
AT410545B (de) * 2001-11-07 2003-05-26 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von chiralen alpha-hydroxycarbonsäuren
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
DK1463497T3 (da) * 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
WO2003053920A1 (en) * 2001-12-13 2003-07-03 Sumika Fine Chemicals Co., Ltd. Crystals of bicalutamide and process for their production
HRP20100067A2 (hr) * 2002-02-07 2010-04-30 University Of Tennessee Research Foundation Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
NZ536513A (en) 2002-05-16 2007-10-26 Novartis Ag Use of EDG receptor binding agents in cancer
EP1534663A4 (de) 2002-06-17 2006-08-30 Univ Tennessee Res Foundation N-verbrückte selektive modulatoren des androgenrezeptors und verfahren zu deren anwendung
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EP1557411B1 (de) 2002-07-12 2012-10-17 Astellas Pharma Inc. N-phenyl-(2r,5s)-dimethylpiperazinderivat
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms
US6818766B2 (en) * 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
EP1562906A4 (de) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation Heterocyclische selektive androgenrezeptormodulatoren und verfahren zu deren anwendung
CN1726019A (zh) * 2002-10-15 2006-01-25 Gtx公司 用选择性雄激素受体调节剂治疗肥胖症
AU2003287077B2 (en) * 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
CA2501874A1 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
PL201541B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania N-(4-cyjano-3-trifluorometylofenylo)-2,3-epoksy-2-metylopropanamidu
PL201540B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania wysokiej czystości N-(4-cyjano-3-trifluorometylofenylo)-3-(4-fluorofenylosulfonylo)-2-hydroksy-2-metylopropanamidu
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JP4603528B2 (ja) 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
WO2004074350A2 (en) * 2003-02-21 2004-09-02 Hetero Drugs Limited Bicalutamide polymorphs
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
DE602004017425D1 (de) 2003-02-27 2008-12-11 Wisconsin Alumni Res Found Pmcol zur behandlung von prostatakrebs
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
AU2003247740A1 (en) * 2003-06-25 2005-02-14 Teva Gyogyszergyar Reszventarsasag Process for purifying and isolating rac-bicalutamide
MXPA05013619A (es) * 2003-06-27 2006-03-10 Orion Corp Nuevos compuestos.
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
JP2005060302A (ja) * 2003-08-12 2005-03-10 Sumitomo Chemical Co Ltd Ｎ−メタクリロイル−４−シアノ−３−トリフルオロメチルアニリンの製造方法および安定化方法
BRPI0413820A (pt) * 2003-08-22 2006-10-24 Ligand Pharm Inc derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
AU2004281708B2 (en) * 2003-10-14 2011-02-17 University Of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
TW200523235A (en) * 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
CA2522874A1 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
ES2394441T3 (es) 2004-04-07 2013-01-31 Novartis Ag Inhibidores de IAP
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
JP2007533726A (ja) 2004-04-22 2007-11-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
DK2289872T3 (en) * 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
ITMI20041222A1 (it) * 2004-06-17 2004-09-17 Cosma S P A Procedimento perfezionato per la sintesi di bicalutamide
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2570047C (en) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxy benzonitriles as androgen modulators
AU2005260816B2 (en) 2004-07-14 2010-12-16 Sumitomo Chemical Company, Limited Method of crystallizing bicalutamide
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
WO2006028969A1 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using na+/k+ atpase inhibitors
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
WO2006029018A2 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
WO2006044916A2 (en) * 2004-10-18 2006-04-27 Bionaut Pharmaceuticals, Inc. Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
AU2005329762A1 (en) * 2005-03-29 2006-10-05 Usv Limited Process for preparation of bicalutamide
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8193357B2 (en) * 2005-06-17 2012-06-05 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds
CA2513356A1 (en) * 2005-07-26 2007-01-26 Apotex Pharmachem Inc. Process for production of bicalutamide
GT200600430A (es) 2005-09-27 2007-05-21 Compuestos de carboxiamina y metodos de uso de los mismos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007057457A2 (en) 2005-11-21 2007-05-24 Novartis Ag Neuroendocrine tumor treatment using mtor inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2006329551A1 (en) * 2005-12-27 2007-07-05 Dabur Pharma Limited An improved process for preparation of Bicalutamide
AU2007220419B2 (en) * 2006-03-03 2012-03-15 Orion Corporation Selective androgen receptor modulators
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN101460467B (zh) 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
MX2008012728A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
RU2447891C2 (ru) 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
BRPI0711385A2 (pt) 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
US7550505B2 (en) * 2006-07-24 2009-06-23 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
BRPI0714526A2 (pt) 2006-08-24 2013-04-30 Univ Tennessee Res Foundation acilanilidas substituÍdas e seus mÉtodos de uso
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (de) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmazeutische kombinationen
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
EP3510959B1 (de) 2007-01-02 2021-03-03 AquaBeam LLC Minimalinvasive vorrichtungen zur behandlung von prostataerkrankungen
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
CA2726734C (en) 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US20090076158A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bicalutamide
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
EP3622910B1 (de) 2008-03-06 2024-07-10 AquaBeam LLC Gewebeablation und kauterisation mit in einem flüssigkeitsstrom getragener optischer energie
MX2010010525A (es) 2008-03-24 2010-10-25 Novartis Ag Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
BRPI0909159A2 (pt) 2008-03-26 2015-11-24 Novartis Ag inibidores baseados em hidroxamato de desacetilases b
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
WO2016037137A1 (en) 2014-09-05 2016-03-10 Procept Biorobotics Corporation Physician controlled tissue resection integrated with treatment mapping of target organ images
ITBO20090235A1 (it) * 2009-04-10 2010-10-11 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi
EP2424853B1 (de) * 2009-04-10 2018-09-19 Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. Nichtsteroidale verbindungen zur modulation des androgenrezeptors, verfahren zur herstellung und deren verwendung
JP5456891B2 (ja) 2009-06-26 2014-04-02 ノバルティス アーゲー Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
IN2012DN01453A (de) 2009-08-20 2015-06-05 Novartis Ag
KR20120050492A (ko) 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
EA201200651A1 (ru) 2009-11-04 2012-12-28 Новартис Аг Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
EP2504339A1 (de) 2009-11-25 2012-10-03 Novartis AG Benzolkondensierte 6-gliedrige sauerstoffhaltige heterocyclische derivate bicyclischer heteroaryle
AU2010329940B2 (en) 2009-12-08 2013-05-16 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
CN101759597B (zh) * 2009-12-31 2013-09-04 上海康鹏化学有限公司 2-三氟甲基-4-氨基苯腈的制备方法
CN103002737A (zh) * 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
EP2582680A1 (de) 2010-06-17 2013-04-24 Novartis AG Biphenyl-substituierte 1,3-dihydro-benzoimidazol-2-ylidenamidderivate
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
FI20105806A0 (fi) * 2010-07-15 2010-07-15 Medeia Therapeutics Ltd Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
JP2013544768A (ja) 2010-09-29 2013-12-19 シルパ メディケア リミテッド ビカルタミドの調製方法
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
WO2012120469A1 (en) 2011-03-08 2012-09-13 Novartis Ag Fluorophenyl bicyclic heteroaryl compounds
ES2541295T3 (es) 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
KR20200016407A (ko) 2011-05-16 2020-02-14 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
BR112013031201A2 (pt) 2011-06-09 2017-01-31 Novartis Ag derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
CA2840315A1 (en) 2011-06-27 2013-01-03 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
EP2755976B1 (de) 2011-09-15 2018-07-18 Novartis AG 6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
PL2785349T5 (pl) 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
SI2794600T1 (en) 2011-12-22 2018-03-30 Novartis Ag 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
EP2794594A1 (de) 2011-12-22 2014-10-29 Novartis AG Chinolinderivate
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
BR112014015274A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibição da interação de bcl2 com parceiros de ligação
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503519A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
US9650382B2 (en) 2012-01-13 2017-05-16 Aranda Pharma Ltd Heteroarylamide derivatives having antiandrogenic properties
TW201332953A (zh) 2012-01-13 2013-08-16 Medeia Therapeutics Ltd 具抗雄激素性質新芳醯胺衍生物
AR089701A1 (es) 2012-01-13 2014-09-10 Medeia Therapeutics Ltd Derivados de arilamida que tienen propiedades antiandrogenicas
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
CN108606773B (zh) 2012-02-29 2020-08-11 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2834216A1 (de) 2012-04-04 2015-02-11 Catylix Inc. Selektive androgenrezeptormodulatoren
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
BR112015003058A2 (pt) 2012-08-13 2017-07-04 Novartis Ag derivados bicíclicos de heteroaril cicloalquildiamina como inibidores de tirosina quinases do baço (syk)
PE20150998A1 (es) 2012-10-02 2015-06-29 Epitherapeutics Aps Inhibidores de histona demetilasas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
RU2510392C1 (ru) * 2012-12-21 2014-03-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма бикалутамида
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
PL2961736T3 (pl) 2013-02-27 2018-08-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
EP3041422A4 (de) 2013-09-06 2017-04-12 Procept Biorobotics Corporation Automatisierte bildgeführte geweberesektion und behandlung
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103772238B (zh) * 2014-01-24 2017-03-22 苏州伊莱特新药研发有限公司 一类新的含酯基芳香丙酰胺化合物及其制备方法和用途
JP6517318B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
AR099890A1 (es) 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
EP4070744A1 (de) 2014-06-30 2022-10-12 PROCEPT BioRobotics Corporation Vorrichtungen für flüssigkeitsstrahlgeweberesektion und kaltkoagulation (aquablation)
CN104151197B (zh) * 2014-07-25 2017-02-22 苏州伊莱特新药研发有限公司 芳香丙酰胺类化合物及其制备方法和应用
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
MA40470A (fr) 2014-08-27 2016-03-03 Gilead Sciences Inc Composés et procédés d'inhibition des histones déméthylases
WO2016079521A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
WO2016079522A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
RU2019115778A (ru) 2015-04-21 2019-06-24 Джи Ти Икс, ИНК. Селективные лиганды - разрушители андрогенных рецепторов (sard) и способы их применения
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN107735085B (zh) 2015-04-21 2021-05-14 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US20210386826A1 (en) 2018-11-05 2021-12-16 Pfizer Inc. Combination for Treating Cancer
CN109438297B (zh) * 2018-12-03 2021-05-14 昆明积大制药股份有限公司 雄激素受体拮抗剂、其制备方法及其应用
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
US12404332B2 (en) 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
CA3188821A1 (en) 2020-08-13 2022-02-17 Lars ANDERS Combination therapy
EP4313034A1 (de) 2021-03-24 2024-02-07 Pfizer Inc. Kombination aus talazoparib und einem antiandrogen zur behandlung von ddr-genmutiertem metastatischem kastrationssensitivem prostatakrebs
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025045058A1 (zh) * 2023-08-28 2025-03-06 中国药科大学 作为雄激素受体拮抗剂的化合物
WO2025067483A1 (zh) * 2023-09-28 2025-04-03 中国药科大学 酰胺类化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133119A (en) * 1961-11-09 1964-05-12 Givaudan Corp Substituted acetanilides and propionanilides
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
CH493198A (de) * 1968-05-06 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
FR2142803A1 (en) * 1971-06-25 1973-02-02 Scherico Ltd 3,4-disubstd anilides - having antiandrogenic activity
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4144270A (en) * 1973-04-19 1979-03-13 Schering Corporation Substituted anilides as anti-androgens
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039684A (en) * 1976-03-25 1977-08-02 Schering Corporation Method for treatment of canine seborrhea
JPS6044294B2 (ja) * 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
FI832644A0 (fi) 1983-07-20
FI83770C (fi) 1991-08-26
EP0100172B1 (de) 1987-08-12
ES8700231A1 (es) 1986-09-16
NL950029I1 (de) 1996-02-01
ES8607936A1 (es) 1986-06-01
EP0100172A1 (de) 1984-02-08
FI83770B (fi) 1991-05-15
LU88769I2 (fr) 1996-11-05
JPH0432061B2 (de) 1992-05-28
IE831732L (en) 1984-01-23
AU556328B2 (en) 1986-10-30
ES544189A0 (es) 1986-09-16
DE3372965D1 (en) 1987-09-17
IE55941B1 (en) 1991-02-27
FI832644A7 (fi) 1984-01-24
NO1996014I1 (no) 1996-12-10
GR79232B (de) 1984-10-22
AU1693783A (en) 1984-01-26
NL950029I2 (nl) 1997-03-03
HU191296B (en) 1987-02-27
DK322783D0 (da) 1983-07-13
ZA835182B (en) 1984-05-30
ES539614A0 (es) 1986-06-01
US4636505A (en) 1987-01-13
NO164974C (no) 1990-12-05
CS399991A3 (en) 1992-06-17
ES539615A0 (es) 1986-06-01
HK92690A (en) 1990-11-16
IL69217A (en) 1987-03-31
PT77087B (en) 1986-01-27
NO164974B (no) 1990-08-27
JPH02131462A (ja) 1990-05-21
PT77087A (en) 1983-08-01
NO832599L (no) 1984-01-24
ES8607915A1 (es) 1986-06-01
NZ204995A (en) 1985-08-30
ES524392A0 (es) 1985-11-01
JPS5933250A (ja) 1984-02-23
MX9203451A (es) 1992-08-01
CA1249823A (en) 1989-02-07
ES8601106A1 (es) 1985-11-01
IL69217A0 (en) 1983-11-30

Similar Documents

Publication Publication Date Title
ATE28864T1 (de) Amide-derivate.
ES8406440A1 (es) Procedimiento para preparar derivados de 2-amino-3-acilamino-6-bencilamino-piridina
ATE15890T1 (de) Ein fungizides indanylbenzamid.
SE8406302L (sv) Nya aminoguanidinderivat och ett forfarande for deras framstellning
DK420682A (da) Fremgangsmaade til fremstilling af triazoloquinazoloner eller salte deraf
ES513487A0 (es) Un procedimiento de preparacion de nuevos compuestos con funcion amida derivados de la piridina.
IE831032L (en) Benzoxazines
ES8502091A1 (es) Procedimiento para preparar derivados de bencilcarbamoilpiridina.
ES419103A1 (es) Procedimiento para la obtencion de ureas n,n'-tetrasusti- tuidas.
ATE33644T1 (de) Harnstoffderivate.
ES527739A0 (es) Un procedimiento para preparar derivados de pirimidina
DK11184A (da) Amidderivater
NO914577L (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte piperazinoalkylbenzoksazin- og -tiazinforbindelser
ATE27153T1 (de) Substituierte pyrimidin-2-one und deren salze.
IT1122376B (it) Prodotti diuretici
ES466026A1 (es) Procedimiento para la obtencion de ditiocarbamatos de hidro-xialquilo.
ATE914T1 (de) Heterocyclische spiroverknuepfte amidine, ihre stereoisomeren und optischen isomeren, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE3276310D1 (en) Arylsulphonyl urea derivatives; their use as herbicides; and herbicidal compositions containing them
ES8502428A1 (es) Procedimiento para preparar nuevas semicarbazidas